Scores here are heuristic signals about sourcing and corroboration across outlets — not verdicts on whether a story is true, and not an endorsement or condemnation of any outlet. How this works
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios. Why it matters: Rival AI giants OpenAI and Anthropic are both pushing into science as they look to expand beyond their core competencies in coding and cybersecurity. State of play: OpenAI will integrate Orchestra's team and technology into Rosalind, its suite of AI models and tools designed for life sciences researchers, the company said. Orchestra's platform allows scientists to delegate tasks like monitoring studies, tracking drug development timelines and identifying potential delays to AI agents. Both companies aim to deploy agents that can connect scientific findings with the decisions and next steps required to advance potential treatments. Financial terms of the acquisition were not disclosed. Between the lines: AI companies don't just want to increase productivity, they want to say they are responsible for, sa
1
independent outlets · 100% owner-diverse
Save this story
Connect "Exclusive: OpenAI has acquired Orchestra Bio" to your own research notes and market positions — Next Level Intelligence links what you save to the assets and notes it actually affects.